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Many diagnostic tests are available to establish Helicobacter pylori infection
status. Most of the tests are accurate though none works perfectly, and no gold
standard for diagnosis exists. Newly developed serum immunoassay kits can
substitute forlaboratory-based enzyme-linked immunosorbent assays, butwhole
blood immunoassays do not yet demonstrate adequate performance characteris-
tics.
Serologic diagnosis of H. pylori remains the most cost-effective option and
should be utilized to establish initial infection in the majority of cases. Ifrapid
urease testing is performed atendoscopy, negativeresults can be confinned with
a subsequent serologic test in those patients with ahighprobability ofinfection.
Obtaining additional gastric tissue at endoscopy to evaluate for bacterial infec-
tion is reasonable if specimens are being taken for a mucosal defect.
Confirmation of bacterial eradication cannot be justified for all post-treatment
patients at present due to the expense. It is important to test for cure in those
patients with complicated ulcerdisease and those withrecurrent symptoms after
therapy.
Multiple diagnostic methods have been developed for the identification of
Helicobacter pylori infection. Such tests are generally divided into those that require
endoscopy, called invasive tests, such as rapid urease tests or histology, and those that do
notrequire endoscopy, or noninvasive tests, such as serology or ureabreath tests. In 1995,
we evaluated all ofthe diagnostic modalities then available to us in a cohort of268 previ-
ously untreated Detroit patients undergoing esophagogastroduodenoscopy [1]. For this
study, H. pylori infection was defined by the majority oftestresults for each patientrather
than by a predefined gold standard. We found that all of the diagnostic tests worked but
none worked perfectly (Table 1). There was complete concordance among all the results
in 134 of 268 patients (50 percent) and near complete agreement, that is at most one test
in variance, in 81 percent. No single test was found to be the statistically superior in the
identification ofbacterial infection. That is, endoscopic rapid urease tests and antral his-
tology with staining were as effective in determining H. pylori status as the noninvasive
tests ofserology and ureabreath test. Endoscopic diagnosis ofinfection couldthus be sup-
planted by office-based tests.
Culture of gastric tissue specimens was not performed as part of the above study,
though such testing is notrequired to diagnose H. pylori, and culture has not gained broad
acceptance in the United States. Immunoassay detection of anti-H. pylori antibodies uti-
lizing either separated serum or whole blood was also not available and hence not includ-
ed in the aforementioned study. Access to office-based serologic tests has improved, and
utilization has increased in the last year. Serum immunoassay tests are comparable to
enzyme-linked immunosorbent assays (ELISA)b in performance and can readily substi-
tute for the laboratory-based assay [2, 3]. Whole blood immunoassays do not function
aTo whom all correspondence should be addressed: Alan F. Cutler, M.D., Section of
Gastroenterology, Sinai Hospital, 6767 West Outer Drive, Detroit, MI 48235. Tel.: (313) 493-6073;
Fax: (313) 493-6213; E-mail: Acutler@pol.net.
bAbbreviations: ELISA, enzyme linked immunosorbent assays.
75Cutler: Accuracy and economics ofHelicobacterpylori diagnosis
Table 1.Accuracy ofdiagnostic tests forH.pylori performed in a cohort of268patients under-
going esophagogastroduodenoscopy.
Sensitivity Specificity
Diagnostic test (percent) (percent)
Invasive
Histology with staining 93 99
Rapid urease test 90 100
Noninvasive
[13C]urea breath test 90 96
IgG serology 91 92
with the same accuracy as the serum tests and should not be utilized until improvements
in clinical results are demonstrated (Table 2).
There has been an decline in the specificity of all serologic tests in last two to three
years. While the specificity for ELISA among a group ofpatients in Detroit in 1992-1993
was 92 percent [1], analysis ofa similar Detroit cohort in 1994-1995 utilizing a commer-
cial serum immunoassay kit yielded a specificity of 77 percent [4]. A multicenter center
study from five centers in the U.S. and Canada presented in 1996 demonstrated a similar
decline in serologic test specificity [2]. Identical results have been reported from other
U.S. sites using various antibody detection kits [5]. The explanation for the decline in
specificity ofserologic tests is probably related to unintentional H. pylorieradication with
clarithromycin. It is unlikely that there has been a change in the antigenic profile of the
bacterium. Additionally, the consistent change in specificity across study centers makes
under-diagnosis of the infection a less plausible explanation. It is most probable that uti-
lization of clarithromycin for unrelated non-gastrointestinal infections has resulted in
unintended bacterial eradication in a significant proportion ofpatients. Monotherapy with
clarithromycin has been shown to cure H. pylori infection in up to 30 to 40 percent of
infected patients [6].
The accuracy ofdiagnostic tests for H. pylori following therapy should be similar to
pretest values, assuming that sufficient time has passed from the eradication attempt to the
follow-up evaluation. Qualitative immunoassays remain positive following cure of the
bacterial infection and should notbe used to confirm eradication. Urea breath tests are the
test of choice to confirm H. pylori cure. In an evaluation of the utility of the [13C]urea
breath test to establish eradication of bacterial infection, Slomianski et al. calculated the
sensitivity and specificity at 88 percent and 94 percent, respectively [7]. Similar results
were obtained in a study from Baylor [8]. The [13C]urea breath test was recently approved
by the U.S. Food and Drug Administration. Its broad implementation has been delayed by
Table 2. Accuracy of office-based antibody for H. pyloni against antral histology evaluated in
five centers across North America [2].
Sensitivity Specificity
Antibody test (percent) (percent)
Serum ELISA 94 78
Serum immunoassay 89 74
Venipuncture whole blood immunoassay 90 67
Fingerstick whole blood immunoassay 83 75
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issues ofcost and reimbursement.
In the approach to patients with suspected ulcer disease or H. pylori infection, it is
better to test for the bacterial infection and selectively treat those who are seropositive
than to empirically treat all patients. The work by Fendrick et al. published in 1995 eval-
uated the cost per ulcer cured as well as the cost per ulcer treated for five alternative man-
agement strategies [9]. The authors demonstrated that the addition of a serologic test to
establish H. pylori infection prior to the initiation of eradication therapy resulted in
approximately the same costs as empiric therapy without testing. Work presented by Dr.
Vakil in abstract form in 1996 directly compared the three management strategies of
empiric H. pylori therapy, serology followed by treatment and urea breath test followed
by treatment [10]. It was shown that the lowest cost per patient cured of symptoms
occurred with serology followed by treatment ($720) as compared with empiric therapy
($1280) or urea breath test plus treatment ($1257). Most recently, Sonnenberg generated
a decision analytic approach to examine the cost-benefit relationships of various options
in dyspepsia and H. pylori infection [11]. He demonstrated that it was less expensive to
test for H. pylori and selectively treat those found to be infected than to empirically treat
all dyspeptic patients. Since testing for bacterial infection prior to treatment reduces
overtreatment ofnoninfected patients and results in costs similar to or probably less than
empiric therapy withouttesting, the nextquestion to address is which testmodality is most
appropriate for the initial diagnosis ofH. pylori.
Recent work to be published later this year modeled the cost-effectiveness of the
available noninvasive testing strategies for H. pylori in dyspeptic office patients [12]. A
decision tree analysis was developed comparing FlexSure HP, HM-CAP ELISA and
[13C]urea breath test utilizing established clinical accuracy and costs. It was concluded
that office based serology is the optimal strategy forthe noninvasive diagnosis ofH. pylori
infection in dyspeptic patients, that whole blood tests are too inaccurate to be cost-effec-
tive at present and that laboratory-based ELISA may not be cost-effective where office-
serology is available. The urea breath test became the initial test of choice when its cost
decreased to below $53.
Diagnosis of H. pylori infection by invasive techniques at esophagogastroduo-
denoscopy is appropriate in certain situations and does offer some advantages in
improved specificity to noninvasive test methods. When gastric tissue specimens are to
be taken for histopathologic evaluation of a mucosal abnormality, biopsing areas away
from the mucosal defect for the presence ofthe bacterial infection is reasonable and adds
little if any cost. Rapid urease tests remain the test of choice to diagnose H. pylori at
endoscopy. Previously, experts in the field suggested that samples for histology be
obtained at the time of endoscopy and then stored until rapid urease test results were
complete. Positive urease results could be accepted and the histologic specimen discard-
ed. Negative urease results would be followed by submission of the stored specimen to
further evaluate for H. pylori. Evaluation ofthis approach was recently undertaken [13].
A cost-analysis for diagnosis of the bacterial infection at initial endoscopy was under-
taken. The rapid urease test was assumed to be the initial test of choice and secondary
test strategies to follow negative urease testresults were evaluated. It was determined that
given a reasonable suspicion for the presence ofH. pylori infection, a negative rapid ure-
ase test should be complimented by a confirmatory antibody test. Secondary histology or
breath tests were not found to be cost-effective strategies.
Confirmation of H. pylori eradication is not required for most patients who have
received therapy. Patients with complicated ulcer disease, such as bleeding, obstruction
or perforation, and patients with recurrent symptoms after treatment, will need to be
evaluated for cure of the infection after antibiotic therapy. At present, this is best per-
formed with repeat esophagogastroduodenoscopy with biopsies or a urea breath test.
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Patients found to have a gastric ulcer at initial endoscopy typically undergo repeat visu-
alization to confirm ulcer healing and evaluate for malignancy. If therapy for H. pylori
is accomplished prior to such follow-up, then histologic specimens may be taken at the
second endoscopy to evaluate the ulcer and to confirm bacterial eradication.
Performance ofureabreath tests in allpost-treatment patients cannotbejustifiedfrom
an economic point ofview [14]. Given an estimated rebleed risk per year for all ulcers of
less than two percent and an H. pylori treatment regimen with 70 percent efficacy, urea
breath tests would need to be performed in 200 patients to prevent one bleed per year. At
a cost of $300 per breath test, $60,000 would be spent per bleed prevented. The cost per
bleed prevented is directly affected by several factors including the rebleed risk per year
and the cost of the test. As the rebleed risk increases and test costs decrease, the cost per
bleed prevented declines. However, as therapies for H. pylori improve and exceed 70 per-
cent efficacy, the number of patients that would need to be tested to prevent one bleed
would rapidly rise. At present, the best follow up after treatment for H. pylori is selective
retesting.
In summary, initial diagnosis ofH. pylori infection in the dyspeptic patient or in the
patient for whom antimicrobial therapy may be warranted should be accomplished with
serology, either laboratory-based ELISA or office-based serum immunoassay. If gastric
tissue of a mucosal defect is to be obtained, additional biopsies may be collected to eval-
uate the infection status. Rapid urease tests may be performed at endoscopy with negative
results confirmed by serology in those patients with a high likelihood for infection.
Confirmation ofbacterial eradication is required in those withcomplicated ulcers orrecur-
rent symptoms after therapy. Confirming successful treatment in all patients is not
presently cost-effective.
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